Cutaneous melanoma · None

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Track	aggressive
Linked regimen	`None`

ID	`IND-FAMMM-CARRIER-INTENSIFIED`
Type	Indication
Status	reviewed 2026-05-18 \| pending_clinical_signoff
Diseases	`DIS-MELANOMA`
Sources	`SRC-NCCN-BCELL-2025` `SRC-NCCN-GENETIC-FAMILIAL-BREAST-OVARIAN-2025`

Notes

STUB — v0.2-B confirmed-carrier intensified track (FAMMM / CDKN2A). Sibling — IND-FAMMM-CARRIER-SURVEILLANCE. §15.2 C4 ≥2-tracks invariant.

Used By

Indication

IND-FAMMM-CARRIER-SURVEILLANCE - IND-FAMMM-CARRIER-SURVEILLANCE

Red flag

RF-FAMMM-CONFIRMED-CARRIER - Confirmed germline pathogenic / likely-pathogenic variant in the CDKN2A (p16-INK4a) gene...